STOCKHOLM, Sweden—Much of the research presented at last week’s European Society of Cardiology (ESC) Congress 2010 offered new ideas on how to tweak current practice, from adjusting heparin doses to choosing alternate antiplatelet drugs. Head-to-head studies of stents and blockbuster trials of new devices, on the other hand, were relatively rare this year.
